Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERZO: Duvelisib vs Gemcitabine or Bendamustine in Relapsed/Refractory Nodal TFH-Phenotype T Cell Lymphoma
2024-516605-23-00Phase 3Authorised
- Sponsor
- Secura Bio
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of copanlisib in Nodal T-cell lymphoma of T-follicular helper origin (nTFHL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 2 more (3 arms), sponsored by Secura Bio. Primary endpoint: Progression-free Survival (PFS) by IRC. Planned start Apr 2025; status: authorised.
02
Drugs
copanlisib
03
Conditions
Nodal T-cell lymphoma of T-follicular helper origin (nTFHL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)T follicular helper cell lymphoma (TFHL)
Beyond the preview
Go deeper on 2024-516605-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516605-23-00.